Market Update
2H 2018 Life Sciences Software Market Update
Madison Park Group (MPG) actively tracks the life sciences software landscape and has been instrumental in strategic deals across the drug development & commercial spectrum.
Through MPG’s time in the space, we’ve noticed a number of trends and developments:
- Continued increase in pharma R&D spend coupled with a need to optimize trial costs and ROI provides ample market opportunity for clinical trial software vendors
- Convergence of software, data and analytical tools to optimize life sciences decision-making, especially through the use of Real World Evidence
- Pre-clinical vendors continue to capitalize on Standard for the Exchange of Nonclinical Data (SEND) regulations through both software and outsourced services
Practice Leaders
2H 2018 Life Sciences Software Market Update
Rohan Khanna
Managing Director
2H 2018 Life Sciences Software Market Update
Jonathan Adler
Managing Director